Atossa Therapeutics (ATOS) Competitors $0.96 -0.02 (-1.66%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATOS vs. PRTC, HUMA, ANAB, CRMD, MREO, XERS, ABVX, MGTX, RNAC, and GLUEShould you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include PureTech Health (PRTC), Humacyte (HUMA), AnaptysBio (ANAB), CorMedix (CRMD), Mereo BioPharma Group (MREO), Xeris Biopharma (XERS), ABIVAX Société Anonyme (ABVX), MeiraGTx (MGTX), Cartesian Therapeutics (RNAC), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Atossa Therapeutics vs. PureTech Health Humacyte AnaptysBio CorMedix Mereo BioPharma Group Xeris Biopharma ABIVAX Société Anonyme MeiraGTx Cartesian Therapeutics Monte Rosa Therapeutics PureTech Health (NASDAQ:PRTC) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Which has more volatility & risk, PRTC or ATOS? PureTech Health has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Does the MarketBeat Community prefer PRTC or ATOS? Atossa Therapeutics received 230 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 65.12% of users gave Atossa Therapeutics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote. CompanyUnderperformOutperformPureTech HealthOutperform Votes945.00% Underperform Votes1155.00% Atossa TherapeuticsOutperform Votes23965.12% Underperform Votes12834.88% Does the media refer more to PRTC or ATOS? In the previous week, PureTech Health had 3 more articles in the media than Atossa Therapeutics. MarketBeat recorded 5 mentions for PureTech Health and 2 mentions for Atossa Therapeutics. Atossa Therapeutics' average media sentiment score of 0.97 beat PureTech Health's score of 0.66 indicating that Atossa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PRTC or ATOS? PureTech Health currently has a consensus target price of $45.00, indicating a potential upside of 121.89%. Atossa Therapeutics has a consensus target price of $7.00, indicating a potential upside of 626.37%. Given Atossa Therapeutics' higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in PRTC or ATOS? 0.0% of PureTech Health shares are held by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 7.6% of Atossa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is PRTC or ATOS more profitable? PureTech Health's return on equity of 0.00% beat Atossa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PureTech HealthN/A N/A N/A Atossa Therapeutics N/A -35.74%-33.51% Which has higher valuation and earnings, PRTC or ATOS? Atossa Therapeutics has lower revenue, but higher earnings than PureTech Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPureTech Health$3.33M145.81-$65.70MN/AN/AAtossa TherapeuticsN/AN/A-$30.09M-$0.22-4.38 SummaryAtossa Therapeutics beats PureTech Health on 9 of the 15 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.23M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-4.3810.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.325.104.794.78Net Income-$30.09M$151.51M$120.07M$225.60M7 Day Performance-13.96%-2.14%-1.90%-1.24%1 Month Performance-19.36%-3.13%11.43%3.06%1 Year Performance31.12%11.51%30.59%16.50% Atossa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Therapeutics1.5209 of 5 stars$0.96-1.7%$7.00+626.4%+32.4%$121.23MN/A-4.388PRTCPureTech Health1.9898 of 5 stars$22.12+8.7%$45.00+103.4%+3.8%$529.60M$3.33M0.00100Gap DownHigh Trading VolumeHUMAHumacyte3.3459 of 5 stars$4.20+2.4%$13.00+209.5%+69.3%$528.61M$1.57M-3.06150Analyst ForecastGap UpANABAnaptysBio2.3125 of 5 stars$17.01+9.1%$45.09+165.1%-25.4%$517.61M$17.16M-2.80100Analyst ForecastCRMDCorMedix1.8468 of 5 stars$8.39+0.1%$15.20+81.2%+147.0%$509.08M$12.26M-10.3530Analyst ForecastNews CoveragePositive NewsMREOMereo BioPharma Group2.0953 of 5 stars$3.27-12.6%$7.40+126.3%+68.3%$507.33M$1M0.0040High Trading VolumeXERSXeris Biopharma3.6033 of 5 stars$3.40+3.7%$4.87+43.1%+73.6%$506.87M$163.91M-7.29290News CoveragePositive NewsABVXABIVAX Société Anonyme2.1863 of 5 stars$7.98+12.2%$38.67+384.5%-27.6%$505.52MN/A0.0061Positive NewsGap DownMGTXMeiraGTx3.867 of 5 stars$6.41+4.7%$23.50+266.6%+25.3%$500.96M$13.93M-5.06300News CoverageRNACCartesian Therapeutics2.2994 of 5 stars$19.06+2.0%$43.00+125.6%-6.3%$484.51M$26M-0.3537Analyst ForecastNews CoverageGLUEMonte Rosa Therapeutics1.9132 of 5 stars$7.78+2.9%$16.00+105.7%+28.3%$477.98M$14.98M-4.1390Analyst DowngradeNews Coverage Related Companies and Tools Related Companies PRTC Alternatives HUMA Alternatives ANAB Alternatives CRMD Alternatives MREO Alternatives XERS Alternatives ABVX Alternatives MGTX Alternatives RNAC Alternatives GLUE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATOS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATOS Stock Alerts